Selective inhibition of electrical conduction within the pulmonary veins by α1-adrenergic receptors activation in the Rat

Pierre Bredeloux1*, Ian Findlay1, Côme Pasqualin1, Mélèze Hocini2,3,4, Olivier Bernus2,3 & Véronique Maupoil1

Pulmonary veins (PV) are involved in the pathophysiology of paroxysmal atrial fibrillation. In the rat, left atrium (LA) and PV cardiomyocytes have different reactions to α1-adrenergic receptor activation. In freely beating atria-PV preparations, we found that electrical field potential (EFP) originated from the sino-atrial node propagated through the LA and the PV. The α1-adrenergic receptor agonist cirazoline induced a progressive loss of EFP conduction in the PV whereas it was maintained in the LA. This could be reproduced in preparations electrically paced at 5 Hz in LA. During pacing at 10 Hz in the PV where high firing rate ectopic foci can occur, cirazoline stopped EFP conduction from the PV to the LA, which allowed the sino-atrial node to resume its pace-making function. Loss of conduction in the PV was associated with depolarization of the diastolic membrane potential of PV cardiomyocytes. Adenosine, which reversed the cirazoline-induced depolarization of the diastolic membrane potential of PV cardiomyocytes, restored full over-shooting action potentials and EFP conduction in the PV.

In conclusion, selective activation of α1-adrenergic receptors results in the abolition of electrical conduction within the PV. These results highlight a potentially novel pharmacological approach to treat paroxysmal atrial fibrillation by targeting directly the PV myocardium.

Atrial fibrillation (AF), the most common arrhythmia in human, is in its paroxysmal stage, mainly induced by ectopic activity arising from the pulmonary veins (PV) myocardial sleeves. Antiarrhythmic drugs used to treat AF are poorly efficient and present a high risk of adverse events. To cure patients with symptomatic AF refractory or intolerant to antiarrhythmic drugs, PV isolation by intra-cardiac catheter ablation is recommended. However, despite a high success rate, this intervention only benefits a small proportion of patients due to the sheer number of AF sufferers worldwide. In addition, arrhythmia recurrence related to PV reconnections are commonly observed and require additional interventions. Therefore, new pharmacological treatments are necessary. To achieve this objective, investigations have mainly been directed towards drugs acting at the atrial level but unfortunately without any success. No successful attempts have been made so far towards the development of PV-specific drugs.

In rat PV strips, norepinephrine has a biphasic effect on the cardiomyocytes resting membrane potential consisting of an initial hyperpolarization followed by a slow depolarization, which precede the appearance of an automatic activity. The selective activation of α1-adrenergic receptors reproduces the depolarization induced by norepinephrine and leads to cardiomyocytes in-excitability. This is not observed in left atria (LA) strips.

The precise physiological role of α1-adrenergic receptors in PV cardiomyocytes is not fully understood but our previous observations allow us to consider the possibility of inhibiting the conduction of PV ectopic activity to the LA using a pharmacological approach. Moreover several studies showed that these receptors are present and functional in the human myocardium, suggesting that this strategy might be transposed to humans. This attractive prospect, led us to investigate the effects of the α1-adrenergic receptors activation on the electrical

1EA7349, Laboratoire STIM, Groupe Physiologie des Cellules Cardiaques et Vasculaires, Université de Tours, Tours, France. 2IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, Bordeaux, France. 3Université de Bordeaux, Centre de Recherche Cardio-Thoracique de Bordeaux, INSERM U1045, Bordeaux, France. 4Bordeaux University Hospital (CHU), Cardiac Electrophysiology and Cardiac Stimulation Team, Bordeaux, France. *email: pierre.bredeloux@univ-tours.fr
Results

Electrical conduction within the PVs-atria preparations in sinus rhythm. Electrical conduction was recorded through EFPs in 10 spontaneously beating PVs-atria preparations (286 ± 12 beats/min) with an 8 electrodes LMEA. A representative preparation and EFP recording is shown in Fig. 1. The earliest EFP signal was recorded on E4 (black arrow, Fig. 1A) at the junction between the PVs ostium and LA roof. The EFP delays showed that electrical activity then spread along the PV (from E4 to E8) and towards the LAA (from E4 to E1). In our experimental conditions, the estimated conduction velocity was similar within the LA and the PV i.e. about 1 m.s⁻¹.

α₁-adrenergic receptor activation selectively suppresses electrical activity within pulmonary veins. In these 10 spontaneously beating PVs-atria preparations, the selective α₁-adrenergic receptor agonist cirazoline (3 × 10⁻⁸ then 10⁻⁷ M) induced a time-dependent loss of electrical activity both in the right and in the left superior pulmonary vein of the rat (see Fig. 2 and Fig. S1 in the Supplementary Data). This effect began between 3 and 10 min (mean 7.4 ± 1.7 min) in the distal region of the PV (E8) and then extended to its base (E4) 15 minutes after the onset of cirazoline superfusion. At the same time electrical conduction was maintained from the LA roof toward the LAA (E4 to E1) (Fig. 2A). A higher concentration of 10⁻⁵ M cirazoline did not have any additional effect (data not shown). This loss of electrical conduction within the PV was dependent upon α₁-adrenergic receptor activation since the addition of the selective α₁-adrenergic receptor antagonist prazosin (5 × 10⁻⁶ M), in the continued presence of cirazoline, progressively restored conduction along the PV from its base in 6.5 ± 1.1 min (E4) to its distal part (E8) in 15.5 ± 1.3 min (Fig. 2B, n = 6).
α₁-adrenergic receptor activation decreases conduction velocity within the pulmonary vein. The next series of experiments were conducted in electrically paced (5 Hz) PVs-LA preparations to avoid the effect of spontaneous sinus drive frequency variation on conduction velocity in different preparations. Stimuli were applied to the apex of the LAA.

In each of 5 preparations, EFP were recorded first in E1, localized in the LAA, and last in E8 localized in the distal part of the PV indicating electrical conduction from the LAA, across the LA and along the PV (Fig. 3A).

Figure 2. (A) A representative recording of electrical activity in a preparation driven by sinus rhythm during the superfusion of $3 \times 10^{-8}$ and $10^{-7}$ M cirazoline. The position of the array was that shown in Fig. 1A. Conduction was lost first in the distal PV (E8) and then progressively down the length of the vein (E7 to E5). Conduction across the LA (E4 to E1) was maintained. (B) Reversal of the effect of cirazoline with prazosin. In a different preparation driven by sinus rhythm, the superfusion of $10^{-7}$ M cirazoline had led to the loss of conduction along the PV (E4 to E8) while retaining conduction across the LA (E4 to E1). The addition of $5 \times 10^{-6}$ M prazosin in the continued presence of cirazoline, led to the progressive recovery of conduction along the PV from its base (E4) to its distal part (E8).
Cirazoline (3 \times 10^{-8} M) induced a time-dependent loss of electrical activity which began in the distal part of the PV (E8) after 5 ± 2 min and progressively extended to its base (E5) after 41 ± 6 min of superfusion. The conduction from the base of the LAA (E1) to the LA (E4) was maintained (Fig. 3A). Prior to this loss of electrical activity,
cirazoline induced a progressive decrease of the conduction velocity of electrical signal between each electrode positioned on the PV (E4 to E8) (Fig. 3B). Thus, the decrease of the conduction velocity first begun at the distal part of the PV and then progressed to its base at the junction with LA. Conduction velocity in the LA roof was not affected (E4 to E1).

In another set of experiments (n = 5), PV-LA preparations were electrically paced from stimulation wires placed on the distal part of the PV. At a frequency of 5 Hz, activation time increased from E8 positioned at the distal part of the PV to E1 positioned in the LA. Superfusion of cirazoline (3 × 10⁻⁸ M) completely abolished the electrical activity in the PV and its conduction to the LA (Fig. 3C). It was noted that the time required to abolish activity in the PV in these preparations (18 ± 2.7 min) was significantly shorter than the time required to obtain complete PV isolation when preparations were paced in the LAA (p = 0.008). In these experimental conditions, we did not observe any modification of conduction velocity prior to the loss of electrical activity.

The loss of electrical conduction induced by α₁-adrenergic receptor activation within the pulmonary veins is due to cardiomyocyte depolarization. Simultaneous recordings of LA and PV AP with intracellular microelectrodes were performed to evaluate the electrophysiological modification induced by cirazoline in 14 PVs-LA preparations electrically paced at 5 Hz (Fig. 4). In PV cardiomyocytes, cirazoline induced a time-dependent depolarization of DMP from −73.9 ± 0.9 mV to −45.1 ± 2.1 mV (p < 0.001) that was associated with a progressive decrease of AP amplitude from 91.1 ± 2.2 mV to 5.4 ± 1.6 mV (p < 0.001). At the same time in the LA, cirazoline had no significant effect upon the DMP or AP amplitude, though it increased APD₉₀ from 36.3 ± 1.8 ms to 44.7 ± 2.5 ms (p < 0.05). In each preparation, full over shooting APs were still recorded in the LA in the presence of 10⁻⁸ M cirazoline when little or no signal could be recorded in the PV. This accounts for the preservation of electrical conduction in the LA (Figs. 2 and 3). The main AP parameters obtained in absence and presence of cirazoline in the PV and in the LA are summarized in Table 1.

α₁-adrenergic receptor activation suppresses EFP conduction from the PV to the LA and restores physiological conduction in preparations in sinus rhythm. Considering these last results, we used the 6 electrodes LMEA to record electrical conduction in the LA of 7 spontaneously beating PVs-atria preparations (253.5 ± 19.7 beats/min) (Fig. 5A). A representative preparation with the electrodes position is shown in Fig. 5E. These preparations were then paced at 10 Hz in the distal part of the PV where high firing rate ectopic foci can occur in human. In these experimental conditions EFP conduction from the sinus node was no longer observed within the LA and the preparations were driven by conduction of EFP evoked in the PV from E6 positioned in the LA roof to E1 positioned in the LAA (Fig. 5B). After 10 ± 2 min of cirazoline 10⁻⁸ M superfusion, electrical stimulation failed to induce one-to-one EFP conduction from the PV (Fig. 5C) and 47 ± 11 seconds later, EFP conduction from the PV failed entirely and signals from the sinus node was restored within the LA (Fig. 5D).

Effect of adenosine upon cirazoline-pretreated pulmonary veins. Finally, the effect of adenosine which has been extensively used in human during PV ablation procedures to unmask dormant conduction was studied. In spontaneously beating preparations (214 ± 24 beats/min, n = 7) in which the electrical conduction within the PV was abolished by cirazoline, adenosine (5 × 10⁻⁶ M) restored electrical conduction in the PV from its base (E4) to its distal part (E8) in 42 ± 11 s (Fig. 6A).

Microelectrode recordings showed that in PVs whose electrical activity has been suppressed by the depolarization induced by cirazoline, the addition of adenosine hyperpolarized the PV cardiomyocyte DMP which resulted in the reappearance of full over-shooting action potentials in the PV myocardium. At the same time, in the LA, in the continued presence of cirazoline, adenosine reduced APD₉₀ from 53.5 ± 3.2 ms to 26.6 ± 1.7 ms (p < 0.01; n = 6) (Fig. 6B,C).

Adenosine by itself increased the DMP of PV cardiomyocytes from −72.8 ± 0.8 mV to −76.8 ± 0.7 mV (p < 0.01, n = 7). This effect was associated with an increase of AP amplitude from 87.8 ± 2.0 mV to 100.7 ± 1.1 mV (p < 0.001) and a reduction in APD 90 from 47.1 ± 1.9 ms to 20.4 ± 0.3 ms (p < 0.001). At the same time, in the LA, adenosine by itself had no significant effect upon the DMP (−73.9 ± 0.9 mV vs. −74.9 ± 0.9 mV, n = 7) and AP amplitude (92.6 ± 2.5 mV vs. 93.6 ± 2.3 mV), though it decreases APD90 from 40.7 ± 3.6 ms to 19.5 ± 1.1 ms (p < 0.001).

Discussion

In this study, we showed for the first time that α₁-adrenergic receptors activation abolishes excitability within PV leading to the loss of electrical conduction without disrupting electrical conduction within the LA.

To perform real-time long-term monitoring of electrical conduction between atria and PV, LMEA made of 6 or 8 recording silver wires electrodes were developed. In fact, commercial multielectrode arrays could not cover the entire area of PV-atria preparation (>20 mm from the base of the LAA to the top of a PV) and do not allow a tight contact between electrodes and tissue to properly record electric signals on all the electrodes. The very high speed of conduction velocity in the rat PV myocardium required electrodes spaced from each other by at least 2 mm (center to center) to visualize the interval between EFP recorded by each electrode positioned along the LA – PV axis. In our experimental conditions, the apparent conduction velocity was about 1 m.s⁻¹ in PV and LA which was in accordance with values previously reported in rat atria.¹²,¹³

The loss of EFP induced by cirazoline in the PV is due to the activation of α₁-adrenergic receptors and not to cellular damages induced by the mechanical stretch applied to the preparation since it was completely reversible by the addition of the α₁-adrenergic antagonist prazosin. In double microelectrode experiments, cirazoline depolarized the DMP of PV cardiomyocytes, leading to the progressive loss of AP in this tissue. Conversely, in all
Figure 4. (A) Simultaneous intracellular microelectrode recordings from the PV (left) and the LA (right) in one preparation during the superfusion of $10^{-6}$ M cirazoline. Pairs of AP are shown at one minute intervals from an otherwise continuous recording stimulated at 5 Hz. (B) The effects of $10^{-6}$ M cirazoline upon DMP (left) and AP amplitude (right) of electrically evoked AP recorded simultaneously in the LA (square symbols) and PV (round symbols). Symbols represent mean ± SEM of results obtained from 14 different preparations which were electrically paced at 5 Hz in the LA. ***p < 0.001 vs basal conditions. ns: no significant difference vs basal condition.

Table 1. Action potential parameters recorded simultaneously in the left atria and the pulmonary veins in basal conditions and at the steady-state of the cirazoline $10^{-6}$ M superfusion. DMP (diastolic membrane potential), AP peak (maximum voltage of action potential), APA (action potential amplitude), P0 dV/dtmax (phase 0 maximum rate of depolarization) and APD90 (action potential duration at 90% of repolarization). Mean ± SEM of results obtained from 14 different preparations electrically paced at 5 Hz in the LA. *P < 0.05 and ***p < 0.001 vs basal condition.
preparations, DMP as well as conduction were maintained in the LA. This is in accordance with previous results demonstrating that α1-adrenergic receptors activation significantly depolarize the membrane of cardiomyocytes in PV but not in LA strips.8

Figure 5. (A) A representative recording of electrical activity in the LA of a preparation driven by sinus rhythm from the right atrium (240 beats/min). The position of the electrode array is indicated in (E). (B) Conduction across the LA in the same preparation driven by 10 Hz electrical stimulation applied to the distal PV under control conditions. (C) After 9 minutes of superfusion of 10−6 M cirazoline, electric stimulation to the PV failed to evoke one-to-one EFP and conduction within the LA. (D) 1 minute later, the 10 Hz electrical stimulation to the PV failed to drive the preparation and conduction from the sinus node was restored within the LA. Stimulus artifacts and EFP are indicated by stars and arrows respectively in (B–D). (E) X indicates the position of the stimulation electrodes used in this series of experiments.
Figure 6. (A) The time course of the recovery of conduction in the PV induced by $5 \times 10^{-5}$ M adenosine. In this preparation which was driven by sinus rhythm, conduction in the PV had been lost after 25 min exposure to $3 \times 10^{-8}$ M cirazoline. The addition of adenosine induced the progressive development of conduction along the PV from its base (E4) to its distal part (E8) in 40 seconds. (B) Segments of a continuous recording of 5 Hz stimulated AP recorded with intracellular microelectrodes simultaneously from the PV (left) and the LA (right) during the superfusion of $10^{-6}$ M cirazoline and then the addition of $10^{-3}$ M of adenosine. (C) The effects of $10^{-3}$ M adenosine upon DMP (left) and AP amplitude (right) of PV (round symbols) and LA (square symbols) AP in the continuous presence of $10^{-6}$ M cirazoline. Symbols represent mean ± SEM of results obtained from 6 different preparations which were electrically paced at 5 Hz in the LA. ***p < 0.001 vs cirazoline.
We also showed that cirazoline did not induce a conduction block at the PV-LA junction, but rather a progressive abolition of the excitability of this tissue. This progressive loss of electrical activity in the PV was preceded by a time-dependent decrease in the conduction velocity which began first in the distal part of the PV and then extended to its base. This early effect in the rat PV distal part could be related to the presence of cardiomyocytes with lower negative resting membrane potential (above −50 mV) compared to cardiomyocytes of the proximal PV (about −75 mV) as reported by 14. This might be due to a variation in the density of certain ionic currents involved in the membrane potential regulation of these cardiomyocytes 15 and could explain why cirazoline take more time to induce a loss of excitability in the base of PV than in its distal part. This hypothesis is reinforced by the observation that adenosine, by increasing the DMP of cirazoline pretreated PV cardiomyocytes, is able to progressively restore conduction first at the base then at the distal part of PV. In fact, it has been shown that adenosine by activating the G-protein regulated K⁺ current, I_Kado 16,17 was able to restore conduction across the depolarized resting membrane potential region induced by an ablation procedure in canine PV 18.

In atrial cardiomyocytes, I_Kado could be inhibited by α₁-adrenergic receptor activation 19,20. In PV cardiomyocytes, the resting membrane potential is less negative than in LA ones 8,21. This difference could be explained by a lower I_K⁺ potassium current 15,21,22 and a higher Na⁺ basal permeability of the PV cardiomyocytes membrane 23 compared to LA cardiomyocytes. Thus, a similar inhibition of I_Kado in PV cardiomyocytes might lead to membrane depolarization in the presence of the background Na⁺ conductance which would no longer be counterbalanced. However, other mechanisms involving the Na⁺/Ca²⁺ exchanger 24 or chloride channels 25,26 might also contribute to the depolarization induced by α₁-adrenergic receptors activation and will require further investigations.

Finally, the cirazoline-induced loss of excitability, which is specific to PV, suggests that a pharmacological approach to treat AF in an early stage could be possible. Since there is no completely satisfactory animal model of paroxysmal AF originating from the thoracic veins 27 to test this hypothesis, we paced spontaneously beating preparations at 10 Hz in the PV. In these conditions, we observed electrical conduction from the PV to the LA which was no longer driven by electric signals from the sinus node. Cirazoline prevented activation of PV cardiomyocytes and thus stopped conduction from the PV allowing the return of the physiological conduction in the LA.

In conclusion, this study demonstrates that in the rat, the α₁-adrenergic receptors activation induces a selective membrane depolarization of PV cardiomyocytes leading to the loss of excitability, which causes electrical impairment in this tissue. This could offer innovative research perspectives for the development of more targeted pharmacological treatments of paroxysmal AF by preventing the triggering of ectopic electrical activities in the PV. As a proof of concept, we showed that cirazoline restored physiological conduction from the sino-atrial node to the LA in preparations driven by high frequency EFP evoked in the PV. Although α₁-adrenergic receptors are expressed and functional in human heart, their activation would obviously lead to systemic adverse events. In prospect, the molecular mechanisms responsible for this depolarization has now to be investigated to find one or more valuable therapeutic targets which will have to be evaluated in human PV.

**Methods**

All applicable international, national and/or institutional guidelines for the care and use of animals were followed. All experiments involving animals were approved by the local institutional ethical committee (Comité d’Éthique en Expérimentation Animale Val de Loire, Tours, France. Permit number 201609071251954).

Male Wistar rats (450 g, CER Janvier, Le Genest St Isle, France) were anesthetized by an intraperitoneal injection of pentobarbital (60 mg/kg). After intravenous injection of heparin (500 UI/kg), the heart-lung block was removed and preparations made up of PV, LA and right atria (RA) were dissected in a dish containing cold cardioplegic solution (in mM: 110 NaCl; 1.2 CaCl₂; 16 KCl; 16 MgCl₂; 10 NaHCO₃; 10 glucose). Experiments were carried out on preparations superfused with Krebs-Henseleit solution (in mM: 119 NaCl; 1.36 CaCl₂; 4.7 KCl; 1.18 KH₂PO₄; 1.17 MgSO₄; 25 NaHCO₃; 5.5 glucose; pH 7.4 equilibrated with 95% O₂ and 5% CO₂) maintained between 35–37°C.

**Multi-electrodes array recordings.** To record extracellular field potentials (EFP) we used custom-made LMEA consisting of 6 or 8 extracellular electrodes made of PFA-coated silver wire (0.76 mm diameter), arranged in line and spaced apart from each other by 2 mm. Recordings were obtained by placing the LMEA on the right or left superior PV-LA axis (for example see Fig. 1A), with the reference electrode in the saline solution. The recording electrodes, labelled E1 to E8, were connected to a data acquisition system (USB-ME64, Multichannel System, Reutlingen, Germany) connected to a computer running the data acquisition software MC_Rack (Multichannel System, Reutlingen, Germany). Sampling frequency for each signal channel was 20 kHz.

In some experiments, preparations were paced via two shielded Ag/AgCl wires positioned either on the left atrial appendage (LAA) or the distal part of a PV and connected to the Multichannel System stimulus generator, STG4008 (Multichannel System, Reutlingen, Germany), which delivered 1 ms duration biphasic square pulse of current at the frequency of 5 or 10 Hz. For analysis, activation times were determined from the point of the maximal negative slope of each EFP.

**Intracellular recording of electrically evoked action potentials.** Electrically evoked action potentials (AP) were recorded simultaneously in the PV (between E7 and E8 in Fig. 1A) and in the LA (close to E2 and E3 in Fig. 1A) with two glass capillary microelectrodes filled with 3 M KCl (20–30 MΩ) connected to a Duo 773 Electrometer amplifier (WPI, Aston, UK). Signals were filtered at 10 kHz low pass, and digitized at a sampling frequency of 40 kHz with a PowerLab 4/25 interface (ADInstruments, Chalgrove, UK). Recordings were acquired on a computer running Chart 5 software. Electrical stimuli consisted of 2 ms duration square wave pulses generated
by a Master-9 programmable stimulator (AMPI, Jerusalem, Israel) through a WPI A360 stimulus isolation unit and delivered to the LA via a pair of fine shielded Ag/AgCl wires approximately positioned near E4 in Fig. 1A.

Analysis of AP parameters was performed with the Peak Parameters Module of Chart 5 software (ADInstruments, Chalgrove, UK). Amplitude of AP duration at a repolarization of 90% (APD90) and the diastolic membrane potential (DMP) were measured at the steady state.

**Statistics.** Data are presented as mean values ± SEM, with the number of experiments indicated as n. Statistical significance were assessed using, Mann-Whitney rank sum test, one-way or two-way repeated measure ANOVA (followed by appropriated post-hoc tests) where appropriate (SigmaStat, V3.5, Systat Software Inc, Point Richmond, CA, USA). A P < 0.05 value was considered to be significant.

**Chemicals and reagents.** Chemicals used in these experiments were of reagent grade. Norepinephrine, prazosin, and adenosine were obtained from Sigma-Aldrich (Saint Quentin- Fallavier, France) and cirazoline from Tocris (Lille, France). They were prepared as stock solutions in distilled water and kept frozen (−20°C) until just prior to dilution in saline solution.

**Data availability**

All data generated or analysed during this study are available from the corresponding author on reasonable request.

Received: 30 December 2019; Accepted: 11 March 2020;

Published online: 25 March 2020

**References**

1. Haïssaguerre, M. *et al.* Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N. Engl. J. Med.* 339, 659–666 (1998).

2. Kirchhof, P. *et al.* 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur. Heart J.* 37, 2893–2941 (2016).

3. Bond, R., Olshansky, B. & Kirchhof, P. Recent advances in rhythm control for atrial fibrillation. *Basic Transl. Sci.* 5, 155–167 (2016).

4. Ouyang, F. *et al.* Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. *Circulation* 123, 2368–2377 (2010).

5. Roten, L. *et al.* Current hot potatoes in atrial fibrillation ablation. *Circ. Arrhythm. Electrophysiol.* 8, 327–346 (2015).

6. Li, D., Sun, H. & Levessa, P. Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety. *Cardiovasc. Hematol. Agents Med. Chem.* 9, 104–116 (2011).

7. Dodd, S. J., Freemantle, N., Furniss, S. S. & Sulke, N. First clinical trial of specific IKCh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation. *Eur. Heart J.* 37, 2391–2398 (2016).

8. Doine, N., Maupol, V., Cosnay, P. & Findlay, I. Catecholaminergic automatic activity in the rat pulmonary vein: electrophysiological differences between cardiac muscle in the left atrium and pulmonary vein. *Am. J. Physiol. Heart Circ. Physiol.* 297, H102–108 (2009).

9. Maupol, V., Bronquard, C., Freslon, J.-L., Cosnay, P. & Findlay, I. Ectopic activity in the rat pulmonary vein can arise from simultaneous activation of alpha1- and beta1-adrenoceptors. *Br. J. Pharmacol.* 150, 899–905 (2007).

10. O’Connell, T. D., Jensen, B. C., Baker, A. J. & Simpson, P. C. Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance. *Pharmacol. Rev.* 66, 308–333 (2014).

11. Thomas, R. C. *et al.* A Myocardial Slice Culture Model Reveals Alpha-1A-Adrenergic Receptor Signaling in the Human Heart. *JACC Basic Transl. Sci.* 1, 155–167 (2016).

12. Iwasaki, Y. -K., Tsuneoka, Y. & Tanaka, H. Electrophysiological and pharmacological properties of the pulmonary vein myocardium. *J. Am. Coll. Cardiol.* 62, 192–198 (2013).

13. Egorov, Y. V., Kuzmin, A. V. & Rosenstrauch, L. V. Electrophysiological Characteristics, Rhythm, Disturbances and Conduction Discontinuities Under Autonomic Stimulation in the Rat Pulmonary Vein Myocardium. *J. Cardiovasc. Electrophysiol.* 26, 1130–1139 (2015).

14. Egorov, Y. V., Kuzmin, A. V. & Rosenstrauch, L. V. Electrophysiological and pharmacological properties of the pulmonary vein myocardium. *J. Cardiovasc. Electrophysiol.* 26, 1130–1139 (2015).

15. Egorov, Y. V. *et al.* Caveolae-Mediated Activation of Mechanosensitive Chloride Channels in Pulmonary Veins Triggers Atrial Arrhythmogenesis. *J. Am. Heart Assoc.* 8, e012748 (2019).
26. Okamoto, Y., Kawamura, K., Nakamura, Y. & Ono, K. Pathological impact of hyperpolarization-activated chloride current peculiar to rat pulmonary vein cardiomyocytes. J. Mol. Cell. Cardiol. 66, 53–62 (2014).

27. Benjamin, E. J. et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation. 119, 606–18 (2009).

Acknowledgements
We thank Armel Bruno and Michel Zapata (Département Génie Electrique et Informatique Industrielle, Tours, France) who provided technical help during this research. This work was supported by the Fondation Coeur & Recherche and by the National Research Agency (ANR-10-IAHU04-LIRYC).

Author contributions
P.B., I.F., M.H., O.B. and V.M.: conception and design of research; P.B., I.F., C.P. and V.M.: experiments, data analysis and interpretation; P.B.: manuscript draft; P.B., I.F., C.P., O.B., V.M.: manuscript editing and revision; P.B., I.F., C.P., M.H., O.B., V.M.: approval of manuscript final version.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-62349-5.

Correspondence and requests for materials should be addressed to P.B.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020